

S262
24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348
EW422
Inflammatory markers in depressed
pregnant women
S. Hergüner
1 ,∗
, H. Toy
2, E. Türen
2, H. Dülger
31
Necmettin Erbakan University, Meram Faculty of Medicine,
Department of Child and Adolescent Psychiatry, Konya, Turkey
2
Necmettin Erbakan Univesity Meram Faculty of Medicine,
Department of Gynecology, Konya, Turkey
3
Necmettin Erbakan University, Meram Faculty of Medicine,
Department of Biochemistry, Konya, Turkey
∗
Corresponding author.
Objectives
In the literature, there are limited number of studies
investigating the relation between depression and inflammatory
markers, including cytokines TNF alfa, and IL-6. In this study, we
aimed to examine the association between TNF alfa, and IL-6 levels
and depression, and anxiety levels in pregnant women.
Methods
The study group consisted of 145 pregnant women who
were their first and singletonpregnancies during their 28–36weeks
of gestation without any chronic physical conditions. They ful-
filled Edinburgh Postpartum Depression Scale (EPDS) and State
Trait Anxiety Inventory (STAI). Their blood was taken after they
completed the questionnaires and levels of TNF alfa, and IL-6 were
examined.
Results
The mean age of the participants were 23.2
±
4.5 years
and mean gestation week was 32.9
±
2.7. According to the EPDS
score, we divided the group into 2, as probable depressive (
≥
12)
and non-depressive (< 12). There were no difference between the
two groups in terms of age, education, and gestational age. Women
with depression had significantly higher TNF alfa, and IL-6 levels
than non-depressive group.
Conclusion
Our findings support that depression in pregnant
women may be related with inflammatory process.
Disclosure of interest
The authors have not supplied their decla-
ration of competing interest.
http://dx.doi.org/10.1016/j.eurpsy.2016.01.540EW423
Immunomodulatory role of
paliperidone in the poly(I:C) model of
schizophrenia
K. MacDowell
1 , 2 ,∗
, E. Munarriz-Cuezva
2 , 3,
D. Martín-Hernández
1 , 2, A. Sayd
1 , 2, B. García-Bueno
1 , 2,
J. Meana
2 , 31
University Complutense of Madrid-School of Medicine,
Pharmacology, Madrid, Spain
2
Centro de Investigación Biomédica en Red en el Área de Salud
Mental, CIBERSAM, Madrid, Spain
3
University of Basque Country UPV/EHU, Bizkaia, Department of
Pharmacology, Bilbao, Spain
∗
Corresponding author.
Introduction
Alterations on the innate inflammatory response
may underlie the pathophysiology of psychiatric diseases, but
the mechanisms implicated remain elusive. Current antipsychotics
modulate pro/anti-inflammatory pathways, but the specific mech-
anisms involved remain elusive. One attractive possibility is the
regulation of the intracellular signalling pathways of the innate
immune receptors Toll-like 3 (TLR3), which triggers antiviral and
inflammatory responses.
Aims
To elucidate the regulatory role of paliperidone onmaternal
immune activation (MIA) induced alterations on TLR3 pathway and
on the two emerging endogenous antiinflammatory/antioxidant
mechanisms NRF2/antioxidant enzymes pathway and the cytokine
milieu regulating M1/M2 polarization in microglia.
Methods
Pregnant mice were treated with the synthetic Toll-like
Receptor 3 (TLR3) agonist Poly(I:C) in gestational day 9 and chron-
ically treated with paliperidone (0,05mg/kg i.p.) in adult offspring.
Animals were sacrificed one day after treatment and behavioral
test. Inflammation oxidative stress-related mediators were ana-
lysed at mRNA and protein level in prefrontal cortex samples. In
addition, behavioral test t-maze was conducted.
Results
Paliperidone prevented TLR3 pathway activation and
the subsequent MIA-induced neuroinflammatory response. Also,
paliperidone induced an increment in the activity and protein
expression of nuclear NRF2, as well as increased mRNA levels of
the antioxidant enzymes HO1, SOD and catalase in the MIA model.
Otherwise, paliperidone increases the antiinflammatory cytokines
levels TGF and IL-10 in favour of a M2 microglia profile and
increased the levels of the M2 cellular markers ArgI and FOLR2.
Conclusions
Themodulation of neuroinflammation and enhance-
ment of endogenous antioxidant/anti-inflammatory pathways by
current andnewantipsychotics could represent an interesting ther-
apeutic strategy for the future.
Disclosure of interest
The authors have not supplied their decla-
ration of competing interest.
http://dx.doi.org/10.1016/j.eurpsy.2016.01.541EW424
Psychosis among HIV-infected
patients –a serious and complex
association
M. Marinho
1 ,∗
, J. Marques
2 , 3, M. Braganc¸ a
1 , 31
São João Hospital Centre, Clinic of Psychiatry and Mental Health,
Porto, Portugal
2
Local Healthcare Unit of Matosinhos, Clinic of Psychiatry, Porto,
Portugal
3
Faculty of Medicine of Porto University, Department of Clinical
Neurosciences and Mental Health, Porto, Portugal
∗
Corresponding author.
Introduction
Psychosis represents an uncommon but serious
complication in the course of HIV infection, and always requires
a careful differential diagnosis.
Objectives
To provide an overview of psychosis in HIV-infected
patients.
Methods
Literature reviewbased onPubMed/MEDLINE, using the
keywords “HIV” and “psychosis”.
Results
Psychosis in HIV-positive individuals can be divided into
psychotic disorders predating HIV infection and new-onset psy-
chotic disorders in HIV-seropositive patients. The pathophysiology
of psychosis in this population is complex and a multifactorial
etiology is likely in most instances. The authors will analyze
them and describe the differences of psychopathological pattern
in first-episode psychosis between HIV-positive and HIV-negative
patients. Antipsychotic agents are the treatments of choice regard-
less of the underlying diagnosis. However, they should always be
used at the lowest possible dose for the shortest possible dura-
tion. Increased sensitivity to extrapyramidal reactions, high risk for
dyslipidemia and hyperglycemia, potential interactions between
HAART and some antipsychotic agents are also important consid-
erations. Importantly, psychosis may be a harbinger of dementia.
Cross-sectional studies have also suggested that psychosis may
adversely impact the morbidity and mortality associated with HIV-
infection.
Conclusions
Psychosis disorders may arise before or at any time
during the course of HIV infection. A solid understanding of the
complex relationship between psychosis and HIV allows for better
evaluation and more effective treatment for psychotic individuals
at risk for or infected with HIV. Thus, both HIV care programs and
psychiatric care clinics should bemade familiar with this important
subject.
Disclosure of interest
The authors have not supplied their decla-
ration of competing interest.
http://dx.doi.org/10.1016/j.eurpsy.2016.01.542